| | Business Summary | | SICOR
Inc.
is
a
specialty
pharmaceutical
company
with
operations
located
in
the
United
States,
Italy
and
Mexico.
SICOR
is
strategically
focused
in
four
complementary
areas:
the
development,
manufacture
and
marketing
of
sterile
multi-source
injectable
pharmaceuticals;
the
development
and
manufacture
of
active
pharmaceutical
ingredients
(API)
for
multi-source
and
branded
products
for
internal
and
third
party
customers;
the
development
of
improved
dosage
forms
and
drug
delivery
systems
for
existing
compounds;
and
the
development
of
bio-equivalent
and
improved
forms
of
existing
biologics. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | SICOR
is
a
specialty
pharmaceutical
company
focused
on
the
development,
manufacturing
and
marketing
of
products
for
worldwide
oncology
and
injectable
pharmaceutical
markets.
For
the
six
months
ended
6/01,
revenues
rose
24%
to
$175.1
million.
Net
income
applicable
to
Common
before
acctg.
change
totalled
$28.7
million,
up
from
$14.1
million.
Revenues
reflect
increased
penetration
of
new
and
existing
products.
Earnings
reflect
an
improved
product
mix
and
reduced
overhead
costs. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Donald Panoz, 66
Chairman | -- | Carlo Salvi, 64
Pres
and CEO | $200K | John Sayward, 49
Exec.
VP, Fin., CFO and Treasurer | 415K | Frank Becker, 65
Exec.
VP, COO, Director | 614K | Michael Cannon, 55
Exec.
VP, Director, Pres of Biotchnology Division | 569K | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/scri.gif)